Posted 11 December 2014
By Patricia Anderson, RAC
Canada is in the final stages of developing an orphan drug policy for drugs affecting populations of 5 in 10,000 people. Bill C-17 has passed the legislature and is awaiting final approval. The new policy will then be open for comment. Fee mitigation, accelerated review and HTA collaboration are incentives but marketing exclusivity is not, although discussions on that topic are taking place. The final hurdle is provincial and private payment plans.
Share this article:
Categories: Prescription drugs, Orphan products, Government affairs, Reimbursement, Features, Canada, FDA, EMA, Health Canada
Tags: orphan drugs, Bill C-17, Vanessa's law, payment plans